Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Innoviva, Inc. (NASDAQ: INVA) is focused on royalty management. Innovivaâs portf...
Innoviva, Inc. (NASDAQ: INVA) is focused on roy...
Turning Point Therapeutics is a clinical-stage precision oncology company with a p...
Turning Point Therapeutics is a clinical-stage ...
Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to address...
Foamix Pharmaceuticals is a specialty pharmaceu...
Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a...
Oramed Pharmaceuticals (NASDAQ: ORMP) was estab...
Phoenix PharmaLabs, Inc. (PPL) is a privately held, pre-clinical stage drug develo...
Phoenix PharmaLabs, Inc. (PPL) is a privately h...
Esperion is a pharmaceutical company passionately committed to developing and comm...
Esperion is a pharmaceutical company passionate...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Join the National Investor Network and get the latest information with your interests in mind.